Free Trial
NASDAQ:EMBC

Embecta (EMBC) Stock Price, News & Analysis

Embecta logo
$20.39 +0.16 (+0.79%)
(As of 05:26 PM ET)

About Embecta Stock (NASDAQ:EMBC)

Key Stats

Today's Range
$19.96
$20.80
50-Day Range
$13.48
$20.83
52-Week Range
$9.93
$21.48
Volume
467,471 shs
Average Volume
414,608 shs
Market Capitalization
$1.19 billion
P/E Ratio
15.10
Dividend Yield
2.94%
Price Target
$23.00
Consensus Rating
Moderate Buy

Company Overview

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Embecta Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
81st Percentile Overall Score

EMBC MarketRank™: 

Embecta scored higher than 81% of companies evaluated by MarketBeat, and ranked 189th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Embecta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Embecta has only been the subject of 2 research reports in the past 90 days.

  • Read more about Embecta's stock forecast and price target.
  • Earnings Growth

    Earnings for Embecta are expected to grow by 9.15% in the coming year, from $2.84 to $3.10 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Embecta is 15.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.36.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Embecta is 15.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.05.

  • Price to Earnings Growth Ratio

    Embecta has a PEG Ratio of 1.08. PEG Ratios above 1 indicate that a company could be overvalued.

  • Percentage of Shares Shorted

    2.28% of the float of Embecta has been sold short.
  • Short Interest Ratio / Days to Cover

    Embecta has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Embecta has recently decreased by 5.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Embecta pays a meaningful dividend of 3.00%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Embecta does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Embecta is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Embecta will have a dividend payout ratio of 19.35% next year. This indicates that Embecta will be able to sustain or increase its dividend.

  • Read more about Embecta's dividend.
  • Percentage of Shares Shorted

    2.28% of the float of Embecta has been sold short.
  • Short Interest Ratio / Days to Cover

    Embecta has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Embecta has recently decreased by 5.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Embecta has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Embecta this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for EMBC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    3 people have added Embecta to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Embecta insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.28% of the stock of Embecta is held by insiders.

  • Percentage Held by Institutions

    93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Embecta's insider trading history.
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

EMBC Stock News Headlines

Embecta (NASDAQ:EMBC) and PAVmed (NASDAQ:PAVM) Critical Analysis
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Contrasting Embecta (NASDAQ:EMBC) and QHSLab (OTCMKTS:USAQ)
BTIG upgrades Embecta Corporation (EMBC) to a Buy
Embecta Corp Appoints Anthony Roth as VP and CAO
See More Headlines

EMBC Stock Analysis - Frequently Asked Questions

Embecta's stock was trading at $18.93 at the start of the year. Since then, EMBC shares have increased by 7.7% and is now trading at $20.39.
View the best growth stocks for 2024 here
.

Embecta Corp. (NASDAQ:EMBC) posted its earnings results on Tuesday, November, 26th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.40 by $0.05. The firm's revenue for the quarter was up 1.5% on a year-over-year basis.

Top institutional shareholders of Embecta include River Road Asset Management LLC (6.03%), Yacktman Asset Management LP (4.38%), FMR LLC (4.17%) and State Street Corp (4.00%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann and David F Melcher.
View institutional ownership trends
.

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/26/2024
Ex-Dividend for 12/18 Dividend
12/06/2024
Dividend Payable
12/18/2024
Today
12/23/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:EMBC
Fax
N/A
Employees
2,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$26.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+12.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$78.30 million
Pretax Margin
3.94%

Debt

Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$3.42 per share
Book Value
($12.80) per share

Miscellaneous

Free Float
57,540,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.25
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:EMBC) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners